

2026 DCNP Fall CE Conference

Event Agenda

Saturday, October 10, 2026 at 7:00am ET - 5:00pm ET

i All times listed in Eastern Time (US & Canada).

Saturday, October 10, 2026

7:00am - 7:45am

Registration & Continental Breakfast

Light continental breakfast with exhibitors

7:45am - 8:15am

Welcome & Federal and State Legislative Update

Donald Bucher

0.5 CE Credits

Donald Bucher's review of the Federal and State Legislative Update will include a review of federal and state pieces of legislation that could potentially impact nurse practitioner practice. He will review how national and state nurse practitioner organizations are working to advance and defend NP practice and will describe ways attendees can support and contribute to the advocacy efforts of both state and national NP organizations.

8:15am - 9:15am

Advancing Women's Heart Health: Current Evidence and Clinical Practice

Tasha Skinner

1.0 CE Credit

The intention of this lecture is to provide an overview of women's cardiovascular health across the lifespan with consideration of emerging trends. Topics will include pregnancy related cardiovascular risk factors, the impact of menopause and HRT on cardiovascular disease as well as providing a summary of the recent updates to hypertension management.

9:15am - 10:15am

Anti-Obesity Medications in Clinical Practice: Prescribing, Monitoring, and Overcoming Barriers to Care

Bonnie Chambers

1.0 CE Credit

In this session, Bonnie Chambers will describe the role of anti-obesity medications in the management of chronic obesity. She will review how to identify appropriate candidates for obesity pharmacotherapy and compare the efficacy and safety of current anti-obesity medications. Finally, she will discuss how to implement evidence-based prescribing and monitoring strategies to improve patient outcomes.

10:15am - 10:30pm

Break with exhibitors

10:30am - 11:30am

Advanced Care Planning: The Conversation That Gives Patients Peace

Latonya Mann

1.0 CE Credit

Dr Mann will discuss the advantage of early advance care planning (ACP) and explain the Five Wishes document

11:30am - 12:30pm

Sleep Apnea: A Major Precursor to Many Primary Care Illnesses

Bernard Addogoh

1.0 CE Credit

12:30pm - 1:30pm

Lunch break with exhibitors

Complimentary lunch with exhibitors

1:30pm - 2:30pm

Prescribing Without Panic - Perinatal Mental Health Medication Management

Emily Martino

1.0 CE Credit

In this session, Emily Martino will review with the audience how to evaluate the risks /benefits of psychotropic medications in pregnancy and lactation vs. risk of untreated mental illness on pregnancy outcomes. Additionally, Martino will discuss how to apply evidence-based framework to best counsel patients about psychiatric medications in perinatal period.

2:30pm - 3:30pm

Implementing a Nurse-Led Type 2 Diabetes Management Protocol in Primary Care

Michael Lockerman

1.0 CE Credit

This presentation will discuss the development and implementation of a nurse-led Type 2 diabetes management protocol in a primary care setting. Diabetes continues to be a significant population health concern, and primary care practices play an important role in providing consistent, evidence-based management. The presentation will describe the practice gap that led to the project, the evidence supporting nurse-driven diabetes management, and the use of the Iowa Model to guide the quality improvement process.

The session will also review the implementation process, including nurse education, standardized diabetes assessments, patient education, documentation expectations, and ongoing chart audits. Participants will learn how standardized nursing workflows can support consistent diabetes care while improving protocol adherence and documentation. The presentation will also discuss barriers, strengths, evaluation methods, and strategies for sustaining improvements after project implementation.

3:30pm - 3:45pm

Break

3:45pm - 4:45pm

Aromatase Inhibitors: An Overview

Carl Popelas

1.0 CE Credit

This session will provide an overview of aromatase inhibitors (AI's); a class of medication commonly used in hormone receptor-positive breast cancer. Participants will learn the basics of estrogen production and how this relates to the appropriate use of aromatase inhibitors. Participants will also learn AI pharmacology, the differences between the two sub-classes of AI's, and common adverse effects. In addition, participants will learn options to help manage adverse effects of the AI's.